Hong Jae Chon
YOU?
Author Swipe
View article: Clinical feasibility of ctDNA in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Clinical feasibility of ctDNA in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab Open
Introduction: The development of targeted therapies and immune checkpoint inhibitors for advanced hepatocellular carcinoma (HCC) reinforces the need for individualized treatment. However, precision medicine is hindered by the lack of manda…
View article: Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers Open
Background We recently published the first real‐world multicenter and multi‐institutional study of cisplatin, gemcitabine, and durvalumab in patients with advanced biliary tract cancer (BTC). Here we present an expanded patient cohort with…
View article: 206P Development of a machine-learning model on pre-treatment characteristics to predict long-term survivorship to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
206P Development of a machine-learning model on pre-treatment characteristics to predict long-term survivorship to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma Open
View article: Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular Features
Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular Features Open
Infiltrative HCC is a clinically aggressive and molecularly distinct subtype of advanced HCC. Morphological classification and type IV infiltrative signatures may guide risk stratification and therapeutic decision-making in advanced HCC tr…
View article: Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab Open
Spontaneously immunogenic hepatocellular carcinoma (HCC), identified by a dense immune cell infiltrate (ICI), responds better to immunotherapy, although no validated biomarker exists to identify these cases. We used machine learning (ML) t…
View article: Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study Open
View article: Utility and outcomes of routine jejunostomy placement following oesophagectomy
Utility and outcomes of routine jejunostomy placement following oesophagectomy Open
Introduction Feeding jejunostomy (FJ) is used widely as a nutritional adjunct in oesophagectomy. However, FJ placement is also associated with additional morbidity. While FJ may be invaluable in some patients, particularly in those who suf…
View article: Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study Open
Introduction: The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiolo…
View article: Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Negative impact of corticosteroid use on outcome in patients with advanced <span>BTCs</span> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population Open
In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real‐world analysis aims to evaluate the impact of conco…
View article: Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma Open
Background Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma (HCC), primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, re…
View article: L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage
L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage Open
Pancreatic cancer (PC) is a worldwide leading cause of cancer-related death. Despite recent progress using immunotherapy with checkpoint inhibitors or targeted agents in various solid tumors, these approaches have not been successful in PC…
View article: 175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
175P Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study Open
View article: Current perspectives and future strategies of chemotherapy for pancreatic cancer: a narrative review
Current perspectives and future strategies of chemotherapy for pancreatic cancer: a narrative review Open
Purpose: Pancreatic cancer remains one of the most lethal malignancies, with a 5-year survival rate below 3% for metastatic disease. Despite advancements in systemic therapy across various solid tumors, pancreatic cancer has seen only incr…
View article: 155 Utility and Outcomes of Routine Jejunostomy Placement Following Uncomplicated Oesophagectomy
155 Utility and Outcomes of Routine Jejunostomy Placement Following Uncomplicated Oesophagectomy Open
Aim Feeding jejunostomy (FJ) is widely used as a nutritional adjunct in oesophagectomy. Nevertheless, it is associated with additional morbidity. While some patients, after major complications, require post-operative prolonged feeding adju…
View article: Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study Open
Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab …
View article: Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study Open
Standard of care first‐line systemic treatment for advanced biliary tract cancer includes chemo‐immunotherapy with gemcitabine, cisplatin, and durvalumab, followed by maintenance durvalumab monotherapy. The present work aims to investigate…
View article: Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Open
View article: Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence Open
View article: Camrelizumab in combination with chemotherapy and targeted therapy improves the prognosis in patients with advanced biliary tract cancer: a single-center retrospective clinical study
Camrelizumab in combination with chemotherapy and targeted therapy improves the prognosis in patients with advanced biliary tract cancer: a single-center retrospective clinical study Open
The application of camrelizumab as neoadjuvant therapy in the treatment of patients with advanced BTC showed encouraging efficacy and safety.
View article: ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab Open
A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.
View article: Epidemiology and genomic features of biliary tract cancer and its unique features in Korea
Epidemiology and genomic features of biliary tract cancer and its unique features in Korea Open
Biliary tract cancer (BTC) is a rare but highly aggressive malignancy that includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, and gallbladder cancer (GBC). While BTC has a low global incidence, its regional va…
View article: Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma Open
Background Newer effective therapies are needed for patients with solid tumors with liver metastases and unresectable hepatocellular carcinoma (HCC). Methods Part 1 (dose exploration) evaluated intrahepatic talimogene laherparepvec (T-VEC)…
View article: Diagnostic cholangioscopy for surgical planning of extrahepatic cholangiocarcinoma
Diagnostic cholangioscopy for surgical planning of extrahepatic cholangiocarcinoma Open
The recent clinical outcomes of multi-regimen chemotherapy included prolonged survival and a high rate of conversion to surgery in Asian patients with advanced biliary tract cancer. The ability of single-operator cholangioscopy (SOC) to de…
View article: Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab Open
Introduction: Atezolizumab-bevacizumab (Atezo-Bev) has become the standard first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, data on subsequent treatment after Atezo-Bev failure are lacking. We a…
View article: 77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab Open
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709)…
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709)…
View article: Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial Open
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709)…
View article: Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma
Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma Open
NCT03079427.
View article: Metal Stents for the Management of Massive Hemobilia in Patients with Hilum-Involving Cholangiocarcinoma Receiving Multi-Regimen Chemotherapy
Metal Stents for the Management of Massive Hemobilia in Patients with Hilum-Involving Cholangiocarcinoma Receiving Multi-Regimen Chemotherapy Open
Recent clinical outcomes of multi-regimen chemotherapy in patients with cholangiocarcinoma (CCC) have shown benefits in terms of overall survival. However, repeated endoscopic biliary drainage (EBD) and serious adverse events negatively af…